| US 7,589,113 B2 | ||
| Substituted oxadiazole compounds and their use as opioid receptor ligands | ||
| Beatrix Merla, Aachen (Germany); Stefan Oberboersch, Aachen (Germany); Bernd Sundermann, Aachen (Germany); Werner Englberger, Stolberg (Germany); Hagen-Heinrich Hennies, Simmerath (Germany); and Heinz Graubaum, Erkner (Germany) | ||
| Assigned to Gruenenthal GmbH, Aachen (Germany) | ||
| Filed on Jun. 20, 2008, as Appl. No. 12/143,550. | ||
| Application 12/143550 is a continuation of application No. PCT/EP2006/012225, filed on Dec. 19, 2006. | ||
| Claims priority of application No. 10 2005 061 427 (DE), filed on Dec. 22, 2005. | ||
| Prior Publication US 2009/0005427 A1, Jan. 01, 2009 | ||
| Int. Cl. A61K 31/4245 (2006.01); A61P 25/00 (2006.01); C07D 271/06 (2006.01); C07D 417/02 (2006.01) | ||
| U.S. Cl. 514—364 [548/131] | 17 Claims |
1. A substituted oxadiazole compound corresponding to formula I:
 X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2;
R1 denotes unsubstituted or mono- or polysubstituted aryl or heteroaryl; or an unsubstituted or mono- or polysubstituted aryl
or heteroaryl group linked via a C1-3 alkylene group;
R2 denotes unsubstituted or mono- or polysubstituted aryl or heteroaryl; or an unsubstituted or mono- or polysubstituted aryl
group linked via a C1-3 alkylene chain; and
R3 and R4 independently denote H; or saturated or unsaturated, branched or unbranched C1-6 alkyl; with the proviso that R3 and R4 are not simultaneously H; or
R3 and R4 together denote —CH2CH2OCH2CH2— or —(CH2)3-6—,
or a salt thereof with a physiologically acceptable acid.
|